A case report reveals that osimertinib rechallenge improves symptoms in a lung cancer patient, suggesting new therapeutic avenues.
A patient with EGFR‐mutant lung cancer developed leptomeningeal carcinomatosis years after osimertinib‐induced ILD. With no other treatment options, palliative osimertinib rechallenge led to rapid neurological improvement and radiological response, without ILD recurrence. This case highlights the potential of carefully monitored osimertinib rechallenge for symptomatic relief in exceptional cases.
No takes yet. Share an insight, caveat, or question.
Nigi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: